Randomised placebo-controlled trial of use of topical recombinant bovine basic fibroblast growth factor for second-degree burns

Wound healing is a dynamic process that could be accelerated by growth factors. We investigated the effect of recombinant bovine basic fibroblast growth factor (rbFGF) on burn healing in a randomised placebo-controlled trial. We recruited 600 patients with superficial or deep second-degree burns. Pa...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet (British edition) 1998-11, Vol.352 (9141), p.1661-1664
Main Authors: Fu, Xiaobing, Shen, Zuyao, Chen, Yulin, Xie, Junhe, Guo, Zhenrong, Zhang, Mingliang, Sheng, Zhiyong
Format: Article
Language:English
Subjects:
Administration, Cutaneous
Adolescent
Adult
Aged
Animals
Biological and medical sciences
Biopsy
Burns
Burns - drug therapy
Burns - pathology
Cattle
Child
Clinical trials
Double-Blind Method
Female
Fibroblast Growth Factor 2 - therapeutic use
Granulation Tissue - drug effects
Granulation Tissue - pathology
Growth factors
Humans
Injury Severity Score
Male
Medical sciences
Middle Aged
Peptides
Pharmacology. Drug treatments
Prospective Studies
Recombinant Proteins - therapeutic use
Skin, nail, hair, dermoskeleton
Wound Healing - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Wound healing is a dynamic process that could be accelerated by growth factors. We investigated the effect of recombinant bovine basic fibroblast growth factor (rbFGF) on burn healing in a randomised placebo-controlled trial. We recruited 600 patients with superficial or deep second-degree burns. Patients received 150 AU/cm 2 daily topical rbFGF (n=300) or placebo (n=300) plus vehicle. We assessed healing by photography, punch-biopsy, and clinical examination. All patients treated with rbFGF had faster granulation tissue formation and epidermal regeneration than those in the placebo group. Superficial and deep second-degree burns treated with rbFGF healed in a mean of 9·9 (SD 2·5) days and 17·0 (4·6) days, respectively, compared with 12·4 (2·7) and 21·2 (4·9) days (p=0·0008 and p=0·0003, respectively). No adverse effects were seen locally or systemically with rbFGF. rbFGF effectively decreased healing time and improved healing quality. Clinical benefits would be shorter hospital stays and the patient's skin quickly becoming available for harvesting and grafting.
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(98)01260-4